PD-LI免疫染色(DAKO 22C3) | 合法醫療器材資訊網

PD-L1-IHC(22C3)-MSD. 詳細內容: 最近更新: 2019-06-18. 列印 · Email. 健保編號. 無. 醫令碼. L11513. 檢體採集. 向病理科申請病理檢體，整個蠟塊送檢。 報告時效. Read More

... 染色平台，針對PD-L1的獨特的一級抗體，即28-8（nivolumab），22C3（​pembrolizumab），SP142（atezolizumab）和SP263（durvalumab）和截止日期。 Read More

2020年4月1日 — 衛生福利部已核准數項PD-L1檢測之第三等級體外診斷醫療器材(class III IVD)，​包括pembrolizumab對應使用之Dako 22C3及Ventana ... Read More

PD-LI免疫染色(DAKO 22C3). 檢驗科別：[分子病理]. 收費碼：46047D. 容器名稱：​無. 採檢容器：. 無採檢容器說明：. 檢體種類(SPECIMEN TYPE)：. 福馬林固定石 ... Read More

PD-L1 IHC 22C3 pharmDx Advancing Immunotherapy Options ... Cytotoxic T cells work to detect and eliminate infected cells and tumor cells from the body. To limit ... Read More

PD-L1 IHC 22C3 pharmDx is indicated as an aid in identifying cervical cancer patients for treatment with KEYTRUDA® (pembrolizumab). Urothelial Carcinoma​ ... Read More

PD-L1 IHC 22C3 pharmDx is indicated as an aid in identifying NSCLC patients for treatment with KEYTRUDA® (pembrolizumab). See the KEYTRUDA product ... Read More

(A) The PD-L1 22C3 pharmDx kit on the Dako ASL48 platform; (B) optimised LDT (primary antibody dilution 1:50, 30-minute incubation); (C) LDT using primary ... Read More

PD-L1 IHC 22C3 pharmDx is indicated as an aid in identifying NSCLC patients for treatment with KEYTRUDA® (pembrolizumab). Summary and explanation. Read More